Synthetic Biology Market: Technological Growth Map over Time to Understand the Industry Growth Rate

According to a new research report by Transparency Market Research (TMR), the presence of a large pool of participants in the global synthetic biology market points towards a competitive vendor landscape. The leading players in this market, such as Gevo Inc., DSM, Bristol Mayer, Life Technologies, LS9 Inc., DuPont Inc., Amyris Inc., and Genomatica Inc., are focusing aggressively on research and development to strengthen their product portfolio and, subsequently, their position in this market. The investments by leading players in this market have also increased considerably, which is reflecting positively on the growth of this market. Bayer, Biosearch Technologies, Green Biologics, Ginkgo Bioworks, and Thermo Fisher Scientific are some of the other prominent players operating in this market, reports the research study.

As per the research report, the global market for synthetic biology, which stood at US$1.8 bn in 2012, is anticipated to expand exponentially at a CAGR of 32.60% during the period from 2013 to 2019 and reach a value of US$13.4 bn by the end of the forecast period. Among products, core products, especially synthetic DNA, led the global market in 2012 and is expected to remain doing so over the next few years, thanks to its higher commercial availability. Genome engineering has surfaced as the most prominent technology utilized in synthetic biotechnology. Researchers expect this technology to continue to lead over the forthcoming years, states the market report.

Want to know the obstructions to your company’s growth in future? Request a PDF sample here

Widening Application Base to Boost Market’s Growth

Synthetic biology technologies and products are finding significant usage in various application areas, thanks to the remarkable increase in their popularity. “Since the organisms engineered with synthetic biology techniques are relatively reasonable, owing to their use in various industrial applications, which also translates in a reduction in the cost of research, the demand for these techniques is increasing considerably across the world,” says a TMR analyst. The increasing involvement of government bodies, research institutes, and large-scale organizations in synthetic biology research activities is likely to support this market over the next few years, notes the research study.

To Know the Segments Analyzed in the Synthetic Biology Market Report, Ask for a Brochure here

Europe to Maintain Lead

Among the geographies, Europe has been leading the global market for synthetic biology since the past few years. With the rise in the government participation and the increase in the funding for the development of synthetic biology, this regional market is anticipated to continue to lead in the years to come. The augmenting application of synthetic biology in healthcare, energy, and environment is also projected to boost the Europe market for synthetic biology over the forthcoming years, states the report.

Genome Engineering Market Growth Prospects, Trends and Forecast up to 2023

The global genome engineering market is an extremely competitive in nature with a presence of a large number of players operating around the world, states a new research report that has been published by Transparency Market Research. The expected entry of several new players is projected to enhance the competitive environment of the market in the coming few years. The key players in the market are focusing on the technological developments and innovations, which is projected to offer potential growth opportunities throughout the forecast period.

In addition to this, the rising research and development activities and the expansion of the product portfolio is expected to encourage the growth of the global genome engineering market in the next few years. Some of the key players operating in the genome engineering market across the globe are Sigma-Aldrich Corporation, Integrated DNA Technologies, Sangamo Biosciences, Thermo Fisher Scientific, GenScript USA, Horizon Discovery, Transposagen Biopharmaceuticals, New England Biolabs, and Lonza Group.

Want to know the obstructions to your company’s growth in future? Request a PDF sample here

According to the market intelligence study by Transparency Market Research, in 2015, the global genome engineering market was worth US$2.30 bn. The market is predicted to reach a value of US$7.21 bn by the end of year 2023, registering a promising 14.20% CAGR between 2015 and 2023.

Adoption of New Technologies to Drive North America Genome Engineering Market

Among the key regional segments, North America is estimated to witness a strong growth in the next few years and is likely to hold a major share of the market in the coming years. A significant rise in the adoption of innovative and advanced techniques and the increasing research and development activities are projected to encourage the growth of the North America market in the next few years. In addition, the rising contribution from the U.S. and the presence of several leading players are predicted to enhance the growth of the market in the near future. Furthermore, Asia Pacific is projected to experience a healthy growth in the coming years, thanks to the rising trend of personalized medicine. Moreover, the rapid development of the biotechnology is likely to enhance the market growth in the near future.

To Know the Segments Analyzed in the Genome Engineering Market Report, Ask for a Brochure here

On the basis of end use, the global market for genome engineering has been categorized into academics, pharmaceutical and biotechnology companies, clinical research institutes, and others. Among these, the academics segment is projected to hold a large share of the market in the next few years. As per the study, this segment is likely to remain in the leading position throughout the forecast period. The rising research and development activities and innovations in this field are projected to enhance the growth of this segment in the next few years.

Growing Demand for Personalized Medicine to Support Market Growth

The rising number of applications areas of genomics and the increasing government funding are considered as the key factors that are projected to enhance the growth of the global genome engineering market in the next few years. The rising prevalence of cancer and several other infectious diseases and the rising production of the genetically modified crops are projected to enhance the growth of the overall market in the coming few years. On the flip side, the lack of skilled professionals and the high cost of genomics equipment are predicted to restrict the growth of the market in the near future. Nonetheless, the increasing use of genome editing in personalized medicine and the rising opportunities offered by the developing economies are further predicted to enhance the growth of the market in the near future.

This information is based on the findings of a research report published by Transparency Market Research (TMR), titled “Genome Engineering Market (Technology – Clustered regularly interspaced short palindromic repeats (CRISPR), Transcription activator-like effector nuclease (TALEN), and Zinc Finger Nuclease (ZFN); Application – Cell Line Engineering, Animal Genome Engineering, and Plant Genome Engineering; End User – Pharmaceutical and Biotechnology Companies, Academics, and Clinical Research Organizations) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2023.”

Medical Tourism Market Size, Analysis and Forecast up to 2025

The global medical tourism market features the presence of a handful of top players, for the market to exhibit a largely consolidated vendor landscape, observes Transparency Market Research (TMR) in a new market intelligence report. Keen players in the medical tourism market are primarily focused on program development that can be attractive for patients from overseas.

To do this, firstly, large players are striving to expand their services, either independently or via tie-ups with small medical facilities. With such expansion, large players are vying to possess state-of-the-art infrastructure to deliver quality healthcare at cost effective prices, adds the report.

Want to know the obstructions to your company’s growth in future? Request a PDF sample here

Key players operating in the global medical tourism market include Asklepios Kliniken GmbH, Bumrungrad International Hospital, Apollo Hospitals Enterprise Limited, Mount Elizabeth Hospital, and KPJ Healthcare Berhad.

TMR finds the global medical tourism market is likely to rise at a robust 14.9% CAGR between 2017 and 2025. Expanding at this pace, the market valued at US$46.46 bn in 2016 is likely to be worth US$160.8 bn by 2025-end.

In terms of medical treatment, orthopedic surgery accounts for the leading revenue to the global medical tourism market. Rising participation in sports and expanding geriatric population globally susceptible to age-related orthopedic ailments is stoking growth of orthopedic surgery segment. Geography-wise, Asia Pacific spells maximum growth potential among other key regions in the medical tourism market. The availability of quality healthcare at low costs makes Asia Pacific a preferred medical tourism destination.

Apart from Expert Medical Consultants, Courteous English speaking Support Staff attracts Westerners to South East Asia

“In Western countries, exorbitant cost of treatment especially surgery is often a deterrent for patients, especially the ones not covered by insurance. This often eggs patients in Western countries to travel to low cost treatment nations such as in South East Asia. Recent economic development in emerging economies of Asia Pacific has been a key reason behind the modernization of healthcare services.

To Know the Segments Analyzed in the Medical Tourism Market Report, Ask for a Brochure here

This, supported by government initiatives and funds from large business houses, healthcare services in emerging economies is witnessing a complete facelift. Medical experts, state-of-the-art medical equipment, plush hospitals, and courteous English speaking personnel are some key attractions because of which medical tourism is receiving a boost in these regions,” says the author of the report.

Another factor fuelling the medical tourism market is the absence of modern healthcare and lack of skilled medical personnel in underdeveloped regions. Due to economic and political reasons, several countries in Africa lack adequate healthcare infrastructure. Diamond traders and business honchos who have made Africa home for wealth creation often travel to developing countries for medical tourism. To serve such needs, the global medical tourism market receives a boost.

Negligence of Nursing Staff and System loopholes hampers Growth

In emerging economies, governments are extending immense support to foster medical tourism. For example, in India, easy transportation, comfortable lodging, and training in multiple foreign languages are closely looked after to serve patients and their families who travel for medical tourism. Large hospital trusts such as the Apollo Group of Hospitals have lodging facilities for individuals accompanying patients to India for medical tourism.

However, incidence of misdiagnosis and negligence on part of nursing staff have had set back on the growth of medical tourism industry.

Nevertheless, gains of quality healthcare experienced by overseas patients in friendly, homely environments outweigh the loopholes in healthcare systems in developing countries. This serves to be a plus for the medical tourism market.

Peptide Therapeutics Market Expected to Witness a Sustainable Growth by 2025

The overall growth of the global peptide therapeutics market rides on the back of rising expenditure on research and development activities by several pharmaceutical organizations. Furthermore, many peptide-based drug companies are making entry into the market. Until 2018, nearly 100 peptide therapeutics were utilized commercially for many clinical indications. In addition to that, around 100 varieties of therapeutics are in the advanced phase of clinical development. Another 200 other types of therapeutics are in the pre-clinical stage.

A few of the prominent companies operating in the global peptide therapeutics market are Teva Pharmaceuticals Industries Ltd., Novartis AG, Takeda Pharmaceutical Company Limited, Pfizer Inc., Bristol-Myers Squibb, GlaxoSmithKline plc, Novo Nordisk A/S, and AstraZeneca PLC.

Transparency Market Research (TMR) has prepared a report which predicts the market to expand at 9.10% CAGR during the assessment period of 2016 – 2024. The research analysts at TMR prophesize that the global peptide therapeutics market is likely to acquire prominence reaching value of US$46.6 mn through 2024.

Want to know the obstructions to your company’s growth in future? Request a PDF sample here

Asia Pacific to Emerge as Fast Growing Region due to Rise in Cases of Cardiovascular Diseases

The global peptide therapeutics market has been segmented into the regions of Latin America, Asia Pacific, Middle East and Africa, Europe, and North America.

From the geographical standpoint, North America is likely to account for a leading share of the global peptide therapeutics market during the forecast period, from 2016 to 2024. The North America market is driven by the prevalence of various lifestyle illnesses such as obesity and type II diabetes in countries like the U.S. and Canada.

North America is closely trailed by Europe where frequent occurrences of cardiovascular diseases, inflammatory diseases, and metabolic disorders propel the peptide therapeutics market toward growth. According to the World Health Organization (WHO), in Europe cardiovascular diseases cause more than half of all the deaths. According to the statistics of European Heart Network, every year nearly 3.9 million people die of cardiovascular diseases in Europe.

Additionally, the Europe peptide therapeutics market is also fuelled by growing investment in the research activities in the pharmaceutical sector.

During the assessment period, it is has been predicted that Asia Pacific region will be one of the rapidly growing markets. The peptide therapeutics market is likely to be driven by rising incidences of cardiovascular diseases in the region. According to the WHO, almost 1 million people die in of cardiovascular diseases in Asia Pacific every year.

To Know the Segments Analyzed in the Peptide Therapeutics Market Report, Ask for a Brochure here

Growing Involvement of Pharmaceutical Companies to Trigger Market Growth

The global peptide therapeutics market is driven by the growing prevalence of lifestyle diseases like obesity and type II diabetes along with life-threatening diseases like cancer.

According to the estimates of The International Agency for Research on Cancer (IARC), in 2018 nearly 18.1 million new incidences of cancer has been recorded and 9.6 million died of cancer. Every one in 6 women and one in 5 men is struck by cancer at least once in their lifetime. The agency also finds that every one in 11 women and one in 8 men pass away from the disease. Prevalence of certain types of cancer is linked with the economic and social development. In the developing countries, a remarkable shift to cancers related to lifestyles from cancer related to poverties has been noticed. Together all these factors are supporting the growth of the global peptide therapeutics market.

Apart from cancer, cardiovascular diseases are also responsible for the expansion of the global peptide therapeutics market. According to the findings of WHO, nearly 17.9 million people dies worldwide of cardiovascular diseases, which is 31% of all the deaths that took place across the globe.

Many peptides therapeutic are designed selectively so as to pick out tumor suppressor proteins, signal transduction pathways, and cell cycles. These peptides therapeutic then go on bind together those target protein for which they are designed. Peptides therapeutics then cause cell death in many cancer cells in vivo and in vitro. They have already exhibited selectivity in targeting and then killing cancer cells without harming the non-cancerous cells. Likewise, for the treatment of cardiovascular diseases, peptide therapeutics copies the functions of mediators that are found in the pathological processes required to treat cardiovascular diseases.

Such high prevalence of cancer and cardiovascular diseases worldwide has triggered leading pharmaceutical companies to start production of peptide therapeutics on a commercial scale. The companies are also making massive investments in research and development in fields like genetic disorders, autoimmune disease, and cancer. These initiatives by pharmaceutical companies are highly likely to support the growth of the global peptide therapeutics market during the review period.

Urinary Tract Infection Treatment Market Set for Rapid Growth and Trend, by 2026

The global urinary tract infection treatment market is projected to amass a large amount of revenues in the coming years. The healthcare industry has shown a deft level of earnestness in dealing with infectious diseases and disorders. Besides, availability of improved research facilities has helped medical scientists in diagnosing the various reasons responsible for urinary tract infection. It is safe to expect that the global urinary tract infection treatment market would become a safe haven for investment in the years to follow. Rapid advancements in the field of nephrology have also played a part in driving market demand.

Transparency Market Research (TMR), in one of its reports, predicts that the global urinary tract infection treatment market would expand at a sluggish CAGR of 3% over the period between 2019 and 2027. Furthermore, the total market value is expected to touch US$ 7.5 Bn in 2027, growing from a value of US$ 5.9 Bn in 2018. The slow rate of growth can be attributed to the delays in approval of several drugs. However, the presence of a seamless healthcare industry shall continue to complement market growth. Moreover, new research initiatives pertaining to medicine and healthcare shall also drive market demand.

Want to know the obstructions to your company’s growth in future? Request a PDF sample here

Approvals from FDA as a Forerunner to Market Growth

The Food and Drug Administration (FDA) has been the harbinger of multiple improvements in the healthcare industry. As the need for improved treatment mechanisms gathers momentum across the world, FDA is playing a defining role in modern medicine. In its latest, FDA approved the use of FETROJA® (cefiderocol) drug for the treatment of urinary tract infections. The occurrence of certain complicated forms of urinary tract infections in adults could be deadly. These types of infections do not have an alternative line of treatment, except the use of heavy drugs. FDA’s new approval is expected to aid the growth of the global urinary tract infection treatment market.

Availability of Improved Medical Facilities to Drive Demand

The adverse effects of insufficient water consumption are widely discussed by medical practitioners and doctors. Furthermore, urinary infections are often an outcome of low water consumption. Therefore, medications for treatment of urinary tract infection are widely distributed across hospitals and pharmacies. Therefore, the global urinary tract infection treatment market is set to undergo revolutionary growth in the years to follow. The advent of better healthcare facilities within nephrology have played a vital role in driving market demand. The geriatric population is highly vulnerable to the incidence of urinary tract infection. Therefore, improvements in geriatric care have also given a thrust to market growth.

To Know the Segments Analyzed in the Urinary Tract Infection Treatment Market Report, Ask for a Brochure here

Some of the leading vendors operating in the global urinary tract infection market are AstraZeneca plc, Pfizer, Inc., Johnson & Johnson, F. Hoffmann La-Roche Ltd., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Novartis AG.

Medical Fiber Optics Market - Brief Analysis by Top Key Players

The   medical fiber optics market is a consolidated one with the presence of a few large companies that hold majority market share, states Transparency Market Research (TMR) in a new research report. Product innovation and development of existing products is the focus of key players in this market to consolidate their position.

Prominent companies to name in the medical fiber optics market are Timbercon Inc., Coherent Inc., Rofin, Vitalcor Inc., Sunoptic Technologies, IPG Photonics, Schott, Leoni AG, Trumph, and American Medical System.

As per the TMR report, the global medical fiber optics market is expected to rise at a CAGR of 7.60% between 2013 and 2019. Rising at this pace, the market is anticipated to peg an overall value of US$1.3 bn by 2019 from US$863.1 mn in 2013. In terms of application, the endoscopes segment displayed dominance in the overall market in 2013; going forward, the segment is poised to display notable growth rate through 2019. The endoscopes segment is predicted to be worth US$543 mn by 2019. By geography, North America holds dominance in the medical fiber optics market as the region boasts high medical service standards and presence of state-of-the-art medical infrastructure. Furthermore, rising demand for minimally invasive surgeries will bode well for North America medical fiber optics market in the near future. North America is expected to continue to lead the global market for medical fiber optics in the forthcoming years.

Want to know the obstructions to your company’s growth in future? Request a PDF sample here

Improvement of Healthcare Infrastructure Fuels Demand

First and foremost, medical fiber optics are increasingly used in minimally invasive procedures. This is driving the medical fiber optics market. With technological advancements of medical equipment leading to shrinking of their size, the medical fiber optics market receives a boost. The global medical fiber optics market is also fuelled by rising demand for progressive technologies and expeditious development in fiber technology.

Growth of application segments of medical fiber optics is also poised to boost the medical fiber optics market. Among the key application segments of medical fiber optics, endoscopes display the leading demand

Technological advancements and improvement in healthcare infrastructure serve to provide opportunities for application segments of medical fiber optics market. This serves to boost the market. Furthermore, with rising demand for minimally invasive surgeries, the application segments of the market will receive a boost.

To Know the Segments Analyzed in the Medical Fiber Optics Market Report, Ask for a Brochure here

Strict Regulations to Monitor Product Specifications Impedes Growth

However, despite several favorable factors fuelling demand for medical fiber optics factors such as strict regulations that monitor if specifications and standards of medical fiber optics are adhered to is a bottleneck to the market’s growth. In addition, risk associated with high intensity of fiber optic lights are some crucial factors inhibiting the global medical fiber optics market. Nevertheless, rising medical standards and improvement in healthcare infrastructure are poised to bring lucrative opportunities to the medical fiber optics market. Furthermore, diverse applications of fiber optics along with their benefits is likely to offer growth opportunities for players in the medical fiber optics market.

CAR-T Cell Therapy Market to Garner Brimming Revenues by 2027

Global CAR-T Cell Therapy Market: Overview

CAR-T cell therapy, which stands for chimeric antigen receptor T-cell therapy, is one of the specialized cancer treatments, wherein a patient’s T-cells are modified in the laboratory to fight against cancer. The T-cells are collected from the patient’s own body via apheresis procedure and are genetically engineered by introducing specific gene that acts as special receptor to bind to specific protein on patients cancer cells. CAR-T cells are then multiplied in the laboratory and then injected into the patient for treatment. The special receptor is called chimeric antigen receptor. Large number of CAR-T cells are being investigated for the treatment of different types of cancer. To date, very few CAR-T cell therapy products have been developed and commercialized and a large number of products are in different stages of clinical approval.

Report Overview @ 

https://www.transparencymarketresearch.com/cart-cell-therapy-market.html

Global CAR-T Cell Therapy Market: Key Trends

The global CAR-T cell therapy market is projected to be driven by significant rise in investments in clinical research and development of CAR-T cell therapeutic drugs by both government as well as private players across the globe. High prevalence of acute lymphoblastic lymphoma (ALL), rise in the number of adult patients with relapsed or refractory large B-cell lymphoma, cytokine release syndrome (CRS) across the globe etc.factors are likely to contribute to growth of the CAR-T cell therapy market during the forecast period. Moreover, high unmet medical needs in the field of oncology, anticipated launch of clinical trial pipeline drugs, and rise in adoption of CAR-T cell therapy treatment are projected to propel the global market during the forecast period. However, complicated process associated with the development of CAR-T cell therapeutic products leads to high cost of final product. This is likely to restrain the global market during the forecast period.

Want to know the obstructions to your company’s growth in future? Request a PDF sample here

Global CAR-T Cell Therapy Market: Segmentation

The global CAR-T cell therapy market can be segmented based on product, application, and region. In terms of product, the global market can be bifurcated into Yescarta and Kymriah. Gilead Sciences, Inc. gained the first-mover advantage in 2017 in the U.S. by launching the first CAR T therapy, Yescarta, approved by the U.S. FDA for the treatment of certain relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL). Furthermore, high prevalence of DLBCL and anticipated commercialization of Yescarta in Europe and other developed countries are projected to drive demand during the forecast period. Kymriah is an immunocellular CAR-T cell therapy developed and commercialized by Novartis AG in August 2017 for the treatment of B-cell acute lymphoblastic leukemia. Based on application, the global market can be classified into acute lymphoblastic lymphoma, and relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL).

To Know the Segments Analyzed in the CAR-T Cell Therapy Market Report, Ask for a Brochure here

Global CAR-T Cell Therapy Market: Regional Analysis

In terms of region, the global CAR-T cell therapy market can be segmented into North America, Europe, Asia Pacific, and Rest of the World. North America is projected to lead the global market during the forecast period. The region’s dominance is attributed to early availability of CAR-T cell therapy products, high prevalence of acute lymphoblastic leukemia, high per capita health care expenditure, and favorable reimbursement policies. The market in Europe is anticipated to expand at the highest CAGR during the forecast period owing to large number of clinical pipeline drugs which are likely to receive marketing and commercialization approval in the near future.

Global CAR-T Cell Therapy Market: Competitive Landscape

Currently, only two companies – Novartis AG and Gilead Sciences, Inc. – have commercialized their CAR-T cell therapy products and account for the entire market share. Other players with CAR-T cell therapy drug candidates in different phases of clinical approval are Celgene Corporation, Eli Lilly and Company, Johnson & Johnson, Amgen, Inc., Cell Medica, and Fate Therapeutics, Inc.

Remote Patient Monitoring Devices Market to Undertake Strapping Growth by the End 2020

The global remote patient monitoring devices market is foreseen in a report by Transparency Market Research (TMR) to show a decently consolidated nature coupled with intense competition between key players. Recently, a larger aggregate share was held by a few prominent names of the market. F. Hoffmann-La Roche Ltd., AMD Global Telemedicine, and Honeywell HomMed LLC are some of the leading companies operating in the market. Merger and acquisition could be a commonly adopted strategy for diversifying product portfolio and gaining a strong market share. Companies are expected to focus on increasing the application of remote patient monitoring devices and take advantage of the availability of technologically developed products to gain traction.

TMR envisages the global remote patient monitoring devices market to earn a US$0.98 bn by the end of 2020. Heart rate monitor categorized under heart monitor could take a leading position in terms of market share. Regionally, the global market is anticipated to find North America securing a lion’s share.

Want to know the obstructions to your company’s growth in future? Request a PDF sample here

Remote Patient Monitoring Considered Ideal amid Rising Healthcare Costs

The demand for remote patient monitoring devices is foretold to see a rise on the back of the growing economic pressure of patient readmission on medical clinics and hospitals. Expanding geriatric patient base and swelling healthcare expenses in the U.S. could be powerful factors supporting the growth of the global remote patient monitoring devices market. This is predicted to positively affect the North America market in the coming years. Rising incidence of diabetes, on the other hand, could increase the requirement of hematology monitoring devices.

Companies are projected to bank on lucrative market opportunities available in emerging regions such as Asia Pacific for attaining a position of strength. The boom of medical tourism in Thailand and India could translate into propelled market growth for remote patient monitoring devices.

To Know the Segments Analyzed in the Remote Patient Monitoring Devices Market Report, Ask for a Brochure here

Lack of Maintenance of Privacy and Security of Data Hinders Market Growth

The global remote patient monitoring devices market is envisioned to have a bright future in terms of growth. However, uncertainty on the part of data security and privacy and lack of their maintenance could hamper the growth of the market. Nonetheless, there could be rewarding prospects birthing with the rise in demand for vital signs monitor as the trend of independent living among geriatrics gains strength. Special monitor could be another product highly demanded in the market due to the increase in application of acute and postoperative care management. This trend could be supported by the rise in prevalence of chronic ailments.

Pain Management Devices Market Poised to Expand at a Robust Pace by 2023

The global pain management devices market features an increasingly competitive landscape marked by rising level of competition among its players. A plethora of players in the market are vying for higher stakes. To this end, they are focusing on unveiling various types of pain management devices with novel technologies in order to reap competitive benefits. Several prominent players have been engaged in expanding their portfolio to consolidate their shares in the global pain management devices market. Rising investments on research and development activities is likely to up the intensity of competition in the pain management devices market in the coming years.

Some of the top players operating in the global pain management devices market are Bio-Medical Research (BMR) Ltd., Halyard Health, Stryker Corp, Baxter International Inc., and Boston Scientific Corp.

Want to know the obstructions to your company’s growth in future? Request a PDF sample here

The global pain management devices market stood US$3.75 billion in 2016 and is projected to touch a valuation of US$6.28 billion by the end of 2023. This represents a CAGR of 7.6% during the forecast period of 2015–2023.

Among the various types of products, neurostimulation devices held the leading share in 2015 and is likely to hold its sway throughout the assessment period. The prevalence of high-impact chronic pain conditions such as those by musculoskeletal is expected to bolster the uptake in the next few years.

Of the key regional markets for pain management devices, North America has been consistently garnering substantial shares over past few years. The regional market for pain management device is anticipated to continue holding prominent shares in the near future, as well. The growth is increasingly fueled by rising incidence sports-related injuries that need pain management devices.

To Know the Segments Analyzed in the Pain Management Devices Market Report, Ask for a Brochure here

Prevalence of Sports-Related Musculoskeletal Injuries offers Robust Boost

The rising demand for better management technologies among patient populations world over is a key factor driving the pain management devices market. Globally rising opioid epidemic has offered an attractive impetus to the demand for pain management technologies. Rising elderly populations, especially in developing and developed nations, has contributed to the prevalence of chronic pain. This is a notable trend bolstering the demand for pain management devices. In numerous countries, the rising incidence of sports and recreation-related injuries leading to hospitalization is bolstering the demand for pain management devices. In particular, the demand is increasingly receiving solid boost from the prevalence of sports-related musculoskeletal injuries in developed countries.

The global pain management devices market is likely to get attractive impetus from several government initiatives and favorable regulatory landscape. In developed nations, reimbursements for spinal cord stimulation devices for patient populations have been fueling the market’s growth in developed countries.

Demand for Better Pain Management Devices for Neuropathic Pain creates Substantial Prospects

The advent of novel pain management devices has created new, exciting avenues in the global market. Increasing pace of commercialization of such devices in recent years has catalyzed rapid market’s expansion.

The global pain management devices market is likely to witness setbacks on account of low level of patient awareness and the high cost of these devices. Moreover, potential side-effects with certain pain management devices have dampened the uptake. The risk of side effects of skin erosion and surgical site infection associated with neurostimulation implants is a case in point.

Nevertheless, the rising incidence of neuropathic pain world over is making room for several lucrative avenues for medical device manufacturers. They are expanding their pipeline of products. Moreover, the rising awareness about the ill effects of prescription pain killers kindles patients’ interest in technologically-advanced pain management devices.

The study presented here is based on a report by Transparency Market Research (TMR) titled “Pain Management Devices Market (Product Type – Electrical Stimulation Devices, Radiofrequency Ablation Devices, Analgesic Infusion Pumps, and Neurostimulation Devices; Application – Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, and Musculoskeletal Pain

Molecular Diagnostics Market - Brief Analysis by Top Key Players

The global molecular diagnostics market is witnessing a significant growth since past few years. The market is likely to register a consolidated competitive scenario in the span of coming years, says an analyst at TMR. The three players leading the market collectively with an aggregated share of 54.0% in 2015 are F. Hoffmann-La Roche AG, Abbott Laboratories, and Danaher Corporation. Various well established firms are investing heavily in the research and development activities, to improve the functionalities of molecular diagnostics tools. The major players are concentrating on improving their product portfolios and are working on key business strategies such as mergers and acquisitions to fortify their presence in the market.

According to the report by Transparency Market Research (TMR), the global molecular diagnostics market is estimated to project a sound CAGR of 11.6% within the forecast period from 2016 to 2025. In 2015, the global molecular diagnostics market was valued around worth of US$7.1 bn. This market figure is anticipated to reach a valuation worth about US$18.9 bn by the end of forecast period.

Want to know the obstructions to your company’s growth in future? Request a PDF sample here

In terms of technology, the global molecular diagnostics market is classified as hybridization, polymerase chain reaction and real-time polymerase chain reaction, transcription-mediated amplification, microarray, and next-gen sequencing. Among these, the PCR segment held the highest share of 39.1% of entire molecular diagnostics market in 2016. This rising demand is attributed to affordability of the PCR segment. Geographically, North America region led the global molecular diagnostics market with a major share of 39.1%. This lead is credited to the rising cases of contagious diseases in the region. Besides, the government is also taking several initiatives to make masses aware about the technology, propelling the additional growth rate in the regional market.

Rising Cases of STDs to Support Demand in Market

With the advent of biomarkers for unfaltered prognosis of chronic ailments such as hepatitis and HIV, the demand in global molecular diagnostics market is also foreseen to get boost. Moreover, increasing research and developmental activities behind the expansion of biomarkers in developed and developing nations is another factor contributing towards the growth of molecular diagnostics market.

To Know the Segments Analyzed in the Molecular Diagnostics Market Report, Ask for a Brochure here

The rising prevalence of STDs, Chlamydia trachomatis and Neisseria gonorrhea that calls for an urgent need of diagnosis of these diseases. In the span of coming years, this is majorly expected to support a rising demand in the molecular diagnostics market. Also, the market growth is also backed consistently by the comfort and simplicity provided to the clinicians. In addition, upgraded biomarker have even reduced the computational time of usual complex stages. 

Poor Reimbursement Policies to Hamper Market Growth

The revenue growth in the global molecular diagnostics market is estimated to be hindered by the delay in approval from FDA and similar administrative bodies. This has resulted in the decline in demand for molecular diagnostics devices in the global market. Furthermore, lack of proper reimbursement policies has also brought down the otherwise progressive growth rate of molecular diagnostics market.

However, the decline in demand can be picked up by improving the quality of personalized treatments in several developed countries. Besides, electrifying growth in healthcare sector in the regions is likely to pump the market development as well in coming years.